biosimilars part 2: regulatory and current status
Published 9 years ago • 3.5K plays • Length 13:25Download video MP4
Download video MP3
Similar videos
-
38:15
biosimilars and biologics
-
14:31
biosimilars and interchangeables - regulatory highlights (27of33) quality – oct. 16-17, 2019
-
42:43
regulatory highlights for biosimilars and interchangeables (9of15) redi – may 29-30, 2019
-
2:47
biosimilars: approval process
-
14:19
regulatory pathway for biosimilars
-
3:00
biosimilars: complex copycat drugs
-
2:28
what are biologic and biosimilar drugs?
-
3:33
biosimilars: manufacturing and inherent variation
-
18:00
biosimilars part 1: history and biology
-
4:05
the biosimilar regulatory pathway
-
5:20
data requirements for biosimilars
-
4:53
biosimilars and the issue of interchangeability
-
1:37
dr. rugo discusses the regulatory process behind biosimilars
-
7:21
biologic drugs and biosimilars
-
57:41
webinar: biologics & biosimilars
-
8:07
biosimilars | what is a biosimilar? | gastrointestinal society
-
20:06
biologics and biosimilars: extrapolation of indications – information for healthcare providers
-
4:05
from biologics to biosimilars: current status and future challenges
-
3:31
interchangeability and postmarketing pharmacovigilance of biosimilars
-
32:37
biologics, biosimilars, and the two-fold u.s. approval framework’s possible impact on prices
-
1:32
the regulation of biosimilars